Bionovo, Inc. to Present Recent Findings of BZL101, Its Anti-cancer Agent, at the American Association for Cancer Research

EMERYVILLE, Calif., April 16 /PRNewswire-FirstCall/ -- Bionovo, Inc. (OTC Bulletin Board: BNVI - News) will present findings on the mechanism of action of its anti-cancer agent BZL101, which is advancing to Phase 1/2 clinical testing for late stage breast cancer at the American Association of Cancer Research (AACR) being held at the Los Angeles Convention Center in Los Angeles, CA, April 14 - 17, 2007.